Prospective Non-interventional, Phase IV Multicentre Study to Assess the Effectiveness, Safety and Tolerability of Elafibranor 80 mg/Day in Participants With Primary Biliary Cholangitis Receiving Treatment in a Real-world Setting
Latest Information Update: 30 May 2025
At a glance
- Drugs Elafibranor (Primary)
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- Acronyms ELFINITY
- Sponsors Ipsen
Most Recent Events
- 31 Jan 2025 Planned End Date changed from 15 Jul 2029 to 15 Jul 2032.
- 31 Jan 2025 Planned primary completion date changed from 15 Jul 2029 to 15 Jul 2032.
- 28 Oct 2024 Planned initiation date changed from 31 Oct 2024 to 30 Nov 2024.